223 related articles for article (PubMed ID: 22568930)
1. From tumor cell metabolism to tumor immune escape.
Villalba M; Rathore MG; Lopez-Royuela N; Krzywinska E; Garaude J; Allende-Vega N
Int J Biochem Cell Biol; 2013 Jan; 45(1):106-13. PubMed ID: 22568930
[TBL] [Abstract][Full Text] [Related]
2. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
3. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
4. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.
Pasero C; Olive D
Immunol Lett; 2013 Mar; 151(1-2):71-5. PubMed ID: 23439006
[TBL] [Abstract][Full Text] [Related]
5. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
6. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
Poggi A; Zocchi MR
Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
9. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
11. Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation.
Delfortrie S; Pinte S; Mattot V; Samson C; Villain G; Caetano B; Lauridant-Philippin G; Baranzelli MC; Bonneterre J; Trottein F; Faveeuw C; Soncin F
Cancer Res; 2011 Dec; 71(23):7176-86. PubMed ID: 22037871
[TBL] [Abstract][Full Text] [Related]
12. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
13. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
14. MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies.
Bubeník J
Folia Biol (Praha); 2005; 51(1):1-2. PubMed ID: 15783085
[No Abstract] [Full Text] [Related]
15. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
16. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies.
Badoual C; Sandoval F; Pere H; Hans S; Gey A; Merillon N; Van Ryswick C; Quintin-Colonna F; Bruneval P; Brasnu D; Fridman WH; Tartour E
Head Neck; 2010 Jul; 32(7):946-58. PubMed ID: 20191626
[TBL] [Abstract][Full Text] [Related]
17. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
19. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
20. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
